Epstein-Barr virus: 40 Years on

Nature Reviews Cancer

Volumn 4, Issue 10, 2004, Pages 757-768

  Young, Lawrence S ^a   Rickinson, Alan B ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; B LYMPHOCYTE RECEPTOR; CD23 ANTIGEN; CD30 ANTIGEN; CD39 ANTIGEN; CD4 ANTIGEN; CD70 ANTIGEN; CD8 ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; COMPLEMENTARY RNA; CYTOTOXIC AGENT; EBNA1 ANTIGEN; EBNA2 ANTIGEN; FAS LIGAND; GANCICLOVIR; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MONOCLONAL ANTIBODY; PROTEIN INHIBITOR; PROTEIN P53; THYMIDINE KINASE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS ANTIGEN; VIRUS DNA; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ADOPTIVE TRANSFER; ANTIGEN SPECIFICITY; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CHILDHOOD CANCER; DRUG TARGETING; ELECTRON MICROSCOPY; ENDEMIC DISEASE; EPSTEIN BARR VIRUS; GENE MUTATION; GENE SEQUENCE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMEDIATE EARLY GENE; MALIGNANT TRANSFORMATION; NASOPHARYNX CARCINOMA; NONHUMAN; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRUS CARCINOGENESIS; VIRUS GENOME; VIRUS INFECTION; VIRUS LATENCY; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANTIGENS, VIRAL; B-LYMPHOCYTES; BURKITT LYMPHOMA; CARCINOMA; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOCOMPROMISED HOST; KILLER CELLS, NATURAL; LYMPHOMA; LYMPHOMA, B-CELL; LYMPHOMA, T-CELL; NASOPHARYNGEAL NEOPLASMS; STOMACH NEOPLASMS; VIRAL PROTEINS; VIRUS LATENCY;

EID: 4944266319     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1452     Document Type: Review

References (138)

1. Epstein, M. A., Barr, Y. M. & Achong, B. G. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 15, 702-703 (1964). The discovery of EBV - the first description of a virus based on the use of the electron microscope.
2. Nemerow, G. R., Mold, C., Schwend, V. K., Tollefson, V. & Cooper, N. R. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complment fragment C3d. J. Virol. 61, 1416-1420 (1987).
3. Borza, C. M. & Hutt-Fletcher, L. M. Alternate replication in B-cells and epithelial cells switches tropism of Epstein-Barr virus. Nature Med. 8, 594-599 (2002).
4. Kieff, E. & Rickinson, A. B. in Fields Virology (eds Knipe, D. M. & Howley, P. M.) 2511-2574 (Lippincott Williams and Wilkins, Philadelphia, 2001).
5. Kieff, E. & Rickinson, A. B. in Fields Virology (eds Knipe, D. M. & Howley, P. M.) 2575-2627 (Lippincott Williams and Wilkins, Philadelphia, 2001).
6. Rowe, M. et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 6, 2743-2751 (1987). First description of distinct forms of EBV latency in Burkitt's lymphoma cells, as compared to EBV-transformed B-cell lines.
7. Wang, F. et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64, 2309-2318 (1990).
8. Levitskaya, J. et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature 375, 685-688 (1995). Demonstration that the Gly-Ala-repeat domain of EBNA1 protects the protein from proteasome-mediated degradation.
9. + T lymphocytes. J. Exp. Med. 199, 459-470 (2004).
10. Lee, S. P. et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J. Exp. Med. 199, 1409-1420 (2004).
11. + T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J. Exp. Med. 199, 1421-1431 (2004).
12. Humme, S. et al. The EBV nuclear antigen1 (EBNA1) enhances B cell immortalisation several thousandfold. Proc. Natl Acad. Sci. USA 100, 10989-10994 (2003).
13. Wilson, J. B., Bell, J. L. & Levine, A. J. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 15, 3117-3126 (1996).
14. Kennedy, G., Komano, J. & Sugden, B. Epstein-Barr virus provides a survival factor to Burkitts lymphomas. Proc. Natl Acad. Sci. USA 100, 14269-14274 (2003).
15. Hammerschmidt, W. & Sugden, B. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature 340, 393-397 (1989).
16. Cohen, J. I., Wang, F., Mannick, J. & Kieff, E. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation. Proc. Natl Acad. Sci. USA 86, 9558-9562 (1989).
17. Grossman, S. R., Johannsen, E., Tong, R., Yalamanchili, R. & Kieff, E. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the Jκ recombination signal binding protein. Proc. Natl Acad. Sci. USA 91, 7568-7572 (1994).
18. Hsieh, J. J. & Hayward, S. D. Masking of the CBF1/RBP Jκ transcriptional repression domain by Epstein-Barr virus EBNA2. Science 268, 560-563 (1995). This and the previous paper were the first to show that EBNA2 influences gene transcription by affecting the notch/RBP-Jκ pathway.
19. Mannick, J. B., Cohen, J. I., Birkenbach, M., Marchini, A. & Kieff, E. The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J. Virol. 65, 6826-6837 (1991).
20. 1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 13, 3321-3328 (1994).
21. Robertson, E., Lin, J. & Kieff, E. The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B and 3C interact win RBP Jκ. J. Virol. 70, 3068-3074 (1996).
22. Zhao, B., Marshal, D. R. & Sample, C. E. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jκ. J. Virol. 70, 4228-4236 (1996).
23. Tomkinson, B., Robertson, E. & Kieff, E. Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J. Virol. 67, 2014-2025 (1993).
24. Parker, G. A. et al. Epstein-Barr virus nuclear antigen (EBNA)3C is an immortalizing oncoprotein with similar properties to adenovirus E1A and papillomavirus E7. Oncogene 13, 2541-2549 (1996).
25. Parker, G. A., Touitou, R. & Allday, M. J. Epstein-Barr virus EBNA3C can disrupte multiple cell cycle checkpoints and induce nuclear division divorced from cytokinesis. Oncogene 19, 700-709 (2000).
26. Radkov, S. A. et al. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription. J. Virol. 73, 5688-5697 (1999).
27. Wang, D., Liebowitz, D. & Kieff, E. An EBV membrane protein expressed in immortalised lymphocytes transforms established rodent cells. Cell 43, 831-840 (1985). First study to show that LMP1 functions as a classic oncogene in a rodent cell-transformation assay.
28. Kaye, K. M., Izumi, K. M. & Kieff, E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc. Natl Acad. Sci. USA 90, 9150-9154 (1993).
29. Henderson, S. et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65, 1107-1115 (1991).
30. Laherty, C. D., Hu, H. M., Opipari, A. W., Wang, F. & Dixit, V. M. The Epstein-Barr virus LMP1 gene product induces A20 zinc finger protein expression by activating nuclear factor κB. J. Biol. Chem. 267, 24157-24160 (1992).
31. Eliopoulos, A. G., Gallagher, N. J., Blake, S. M., Dawson, C. W. & Young, L. S. Activation of the p38 mitogen-activated protein kinase pathway by Epstein-Barr virus-encoded latent membrane protein 1 coregulates interleukin-6 and interleukin-8 production. J. Biol. Chem. 274, 16085-16096 (1999).
32. Eliopoulos, A. G. et al. Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-κB pathway involving TNF receptor-associated factors. Oncogene 14, 2899-2916 (1997).
33. Mosialos, G. et al. The Epstein-Barr virus transforming protein LMP1 engages signalling proteins for the tumour necrosis factor receptor family. Cell 80, 389-399 (1995). Important study showing that LMP1 functions as a constitutively activated member of the TNF receptor family by interacting with common accessory proteins.
34. Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16, 6131-6140 (1997).
35. Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17, 1700-1709 (1998).
36. Uchida, J. et al. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses. Science 286, 300-303 (1999). In vivo demonstration that LMP1 can partially substitute for absence of the CD40 receptor.
37. Eliopoulos, A. G. & Young, L. S. LMP1 structure and signal transduction. Semin. Cancer Biol. 11, 435-444 (2001).
38. Longnecker, R. Epstein-Barr virus latency: LMP2, a regulator or means for Epstein-Barr virus persistence? Adv. Cancer Res. 79, 175-200 (2000).
39. Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411 (1998).
40. Scholle, F., Bendt, K. M. & Raab-Traub, N. Epstein-Barr virus LMP2A transforms epithelial cells, inhibits cell differentiation, and activates Akt. J. Virol. 74, 10681-10689 (2000).
41. Portis, T., Dyck, P. & Longnecker, R. Epstein-Barr virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102, 4166-4178 (2003).
42. Portis, T. & Longnecker, R. Epstein-Barr virus LMP2A interferes with global transcription factor regulation when expressed during B-lymphocyte development. J. Virol. 77, 105-114 (2003).
43. Takada, K. & Nanbo, A. The role of EBERs in oncogenesis. Semin. Cancer Biol. 11, 461-167 (2001).
44. Nanbo, A., Inoue, K., Adachi-Takasawa, K. & Takada, K. Epstein-Barr virus RNA confers resistance to interteron-α-induced apoptosis in Burkitt's lymphoma. EMBO J. 21, 954-965 (2002).
45. Ruf, I. K., Rhyne, P. W., Yang, C., Cleveland, J. L. & Sample, J. T. Epstein-Barr virus small RNAs potentiate tumourigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J. Virol. 74, 10223-10228 (2000).
46. Hitt, M. M. et al. EBV gene expression in an NPC-related tumour. EMBO J. 8, 2639-2651 (1989).
47. Deacon, E. M. et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177, 339-349 (1993).
48. Chen, H., Smith, P., Ambinder, R. F. & Hayward, S. D. Expression of Epstein-Barr virus BamHI-A rightward transcripts in latently infected B cells from peripheral blood. Blood 93, 3026-3032 (1999).
49. Karran, L., Gao, Y., Smith, P. R. & Griffin, B. E. Expression of a family of complementary-strand transcripts in Epstein-Barr virus-infected cells. Proc. Natl Acad. Sci. USA 89, 8058-8062 (1992).
50. Smith, P. R. et al. Structure and coding content of CST (BART) family RNAs of Epstein-Barr virus. J. Virol. 74, 3082-3092 (2000).
51. Decaussin, G., Sbih-Lammali, F., de Turenne-Tessier, M., Bouguermouh, A. & Ooka, T. Expression of BARF1 gene encoded by Epstein-Barr virus in nasopharyngeal carcinoma biopsies. Cancer Res. 60, 5584-5588 (2000).
52. zur Hausen, A. et al. Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: expression of the transforming BARF1 gene. Cancer Res. 60, 2745-2748 (2000).
53. Sheng, W., Decaussin, G., Sumner, S. & Ooka, T. N-terminal domain of BARF1 gene encoded by Epstein-Barr virus is essential for malignant transformation of rodent fibroblasts and activation of BCL-2. Oncogene 20, 1176-1185 (2001).
54. Anagnostopoulos, I., Hummel, M., Kreschel, C. & Stein, H. Morphology, immunophenotype and distribution of latently and/or productively Epstein-Barr virus-infected cells in acute infectious mononucleosis: implications for the interindividual infection route of Epstein-Barr virus. Blood 85, 744-750 (1995).
55. Kurth, J. et al. Epstein-Barr virus-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13, 485-495 (2000).
56. Babcock, G. J., Decker, L. L., Volk, M. & Thorley-Lawson, D. A. EBV persistence in memory B cells in vivo. Immunity 9, 395-404 (1998). Important series of papers from the same group suggesting that EBV exploits the physiology of normal B-cell differentiation to persist within the memory-B-cell pool of the immunocompetent host.
57. Hochberg, D. et al. Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J. Virol. 78, 5194-5204 (2004).
58. Babcock, G. J., Hochberg, D. & Thorley-Lawson, D. A. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity 13, 497-506 (2000).
59. Laichalk, L. L., Hochberg, D., Babcock, G. J., Freeman, R. B. & Thorley-Lawson, D. A. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 16, 745-754 (2002).
60. + T cell responses from primary to persistent phases of Epstein-Barr virus infection. J. Exp. Med. 195, 893-905 (2002).
61. Young, L. et al. Expression of Epstein-Barr virus transformation- associated genes in tissues of patients with EBV lymphoproliferative disease. N. Engl. J. Med. 321, 1080-1085 (1989). First demonstration of EBV latent protein expression in post-transplantation lymphomas.
62. Timms, J. M. et al. Target cells of Epstein-Barr virus (EBV)-positive post-transplant lymphoproliferative disease: similarities to EBV-positive Hodgkin's lymphoma. Lancet 361, 217-223 (2003).
63. Capello, D. et al. Molecular histogenesis of post-transplantation lymphoproliferative disorders. Blood 102, 3775-3785 (2003).
64. Hsu, J. L. & Glaser, S. L. Epstein-Barr virus-associated malignancies: epidemiologic patterns and etiologic implications. Crit. Rev. Oncol. Hematol. 34, 27-53 (2000).
65. Kanzler, H., Kuppers, R., Hansmann, M. L. & Rajewsky, K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumour clone derived from (crippled) germinal center B cells. J. Exp. Med. 184, 1495-1505 (1996). One of the first studies to isolate the malignant cells of Hodgkin's lymphoma and definitively determine the origin of these cells by immunoglobulin-gene sequencing.
66. Kuppers, R. Molecular biology of Hodgkin's lymphoma. Adv. Cancer Res. 84, 277-312 (2002).
67. Schwering, I. et al. Loss of the B lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101, 1505-1512 (2003).
68. Polack, A. et al. c-myc activation renders proliferation of Epstein-Barr virus (EBV)-transformed cells independent of EBV nuclear antigen 2 and latent membrane protein 1. Proc. Natl Acad. Sci. USA 93, 10411-10416 (1996).
69. Kovalchuk, A. L. et al. Burkitt lymphoma in the mouse. J. Exp. Med. 192, 1183-1190 (2000).
70. Li, Z. et al. A global transcriptional regulatory role for c-myc in Burkitt's lymphoma. Proc. Natl Acad. Sci. USA 100, 8146-8169 (2003).
71. Lindstrom, M. S. & Wiman, K. G. Role of genetic and epigenetic changes in Burkitt lymphoma. Semin. Cancer Biol. 12, 381-387 (2002).
72. Chapman, C. J., Mockridge, C. I., Rowe, M., Rickinson, A. B. & Stevenson, F. K. Analysis of V-H genes used by neoplastic B cells in endemic Burkitts lymphoma shows somatic hypermutation and intraclonal heterogeneity. Blood 85, 2176-2181 (1995).
73. Klein, U., Klein, G., Ehlin-Henriksson, B., Rajewsky, K. & Kuppers, R. Burkitt's lymphoma is a malignancy of mature B cells expressing somatically mutated V-region genes. Mol. Med. 1, 495-505 (1995).
74. Harris, R. S., Croom-Carter, D., Rickinson, A. B. & Neuberger, M. S. Epstein-Barr virus and the somatic hypermutation of immunoglobulin genes in Burkitt's lymphoma cells. J. Virol. 75, 10488-10492 (2001).
75. Kelly, G., Bell, A. & Rickinson, A. B. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA1. Nature Med. 8, 1098-1104 (2002).
76. Pajic, A. et al. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int. J. Cancer 93, 810-816 (2001).
77. Kang, M. S., Hung, S. C. & Kieff, E. Epstein-Barr virus nuclear antigen 1 activates transcription from episomal but not integrated DNA and does not alter lymphocyte growth. Proc. Natl Acad. Sci. USA 98, 15233-15238 (2001).
78. Kiss, C. et al. T cell leukaemia I oncogene expression depends on the presence of Epstein-Barr virus in the virus-carrying Burkitt lymphoma lines. Proc. Natl Acad. Sci. USA 100, 4813-4818 (2003).
79. Boshoff, C. & Weiss, R. AIDS-related malignancies. Nature Rev. Cancer 2, 373-582 (2002).
80. Araujo, I. et al. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma. J. Pathol. 187, 326-330 (1999).
81. Jones, J. F. et al. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N. Engl. J. Med. 318, 733-741 (1988).
82. Harabuchi, Y. et al. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet 335, 128-130 (1990).
83. Kanegane, H., Nomura, K., Miyawaki, T. & Tosato, G. Biological aspects of Epstein-Barr virus (EBV)-infected lymphocytes in chronic active EBV infection and associated malignancies. Crit. Rev. Oncol. Haematol. 44, 239-249 (2002).
84. Kikuta, H. et al. Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawaski-like disease. Nature 333, 455-457 (1988).
85. Kanavaros, P. et al. Nasal T-cell lymphoma: a clinicopathologic entity associated with peculiar phenotype and with Epstein-Barr virus. Blood 81, 2688-2695 (1993).
86. Raab-Traub, N. Epstein-Barr virus in the pathogenesis of NPC. Semin. Cancer Biol. 12, 431-441 (2002).
87. Yu, M. C. & Yuan, J. M. Epidemiology of nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 421-429 (2002).
88. Yu, M. C., Ho, J. H., Lai, S. H. & Henderson, B. E. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong. Cancer Res. 46, 956-961 (1986).
89. Raab-Traub, N. & Flynn, K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 47, 883-889 (1986).
90. Zeng, Y. Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv. Cancer Res. 44, 121-138 (1985).
91. Chan, A. T. C. et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J. Natl Cancer Inst. 94, 1614-1619 (2002).
92. Pathmanathan, R. et al. Undifferentiated, non-keratinising, and squamous cell carcinoma of the nasopharynx. Variants of Epstein-Barr virus-infected neoplasia. Am. J. Pathol. 146, 1355-1367 (1995).
93. Shibata, D. & Weiss, L. M. Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 140, 769-774 (1992).
94. Tokunaga, M. et al. Epstein-Barr virus in gastric carcinoma. Am. J. Pathol. 143, 1250-1254 (1993).
95. Imai, S. et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc. Natl Acad. Sci. USA 91, 9131-9135 (1994).
96. Schneider, B. G. et al. Loss of p16/CDKN2A tumour suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and antomic location in the body of the stomach. Hum. Pathol. 31, 45-50 (2000).
97. Lee, H. S., Chang, M. S., Yang, H. K., Lee, B. L. & Kim, W. H. Epstein-Barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin. Cancer Res. 10, 1698-1705 (2004).
98. zur Hausen, A. et al. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J. Clin. Pathol. 57, 487-491 (2004).
99. Bonnet, M. et al. Detection of Epstein-Barr virus in invasive breast cancers. J. Natl Cancer Inst. 91, 1376-1381 (1999).
100. Sugawara, Y. et al. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterised by the absence of EBV-encoded small RNA expression. Virology 256, 196-202 (1999).
101. Murray, P. G. et al. Reactivity with a monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res. 63, 2338-2343 (2003).
102. Li, J.-H. et al. Tumour-targeted gene therapy for nasopharyngeal carcinoma. Cancer Res. 62, 171-178 (2002).
103. Li, J.-H. et al. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol. Ther. 8, 964-973 (2003).
104. Israel, B. F. & Kenney, S. C. Virally targeted therapies for EBV-associated malignancies. Oncogene 22, 5122-5130 (2003).
105. Feng, W.-H., Hong, G., Delecluse, H. J. & Kenney, S. C. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J. Virol. 78, 1893-1902 (2004).
106. Ambinder, R. F., Robertson, K. D. & Tao, Q. DNA methylation and the Epstein-Barr virus. Semin. Cancer Biol. 9, 369-375 (1999).
107. Chan, A. T. C. et al. Azacitidine induces demethylation of the Epstein-Barr virus genome in tumours. J. Clin. Oncol. 22, 1373-1381 (2004).
108. Chodosh, J. et al. Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. J. Infect. Dis. 177, 1194-1201 (1998).
109. Slobod, K. S. et al. Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system. Lancet 356, 1493-1494 (2000).
110. Piche, A., Kasono, K., Johanning, F., Curiel, T. J. & Curiel, D. T. Phenotypic knockout of the latent membrane protein 1 of Epstein-Barr virus by an intracellular single-chain antibody. Gene Ther. 5, 1171-1179 (1998).
111. Kenney, J. L., Guinness, M. E., Curiel, T. & Lacy, J. Antisense to the Epstein-Barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and Bcl-2 expression and promotes apoptosis in EBV-immortalised B cells. Blood 92, 1721-1727 (1998).
112. Cahir-McFarland, E. D., Davidson, D. M., Schauer, S. L., Duong, J. & Kieff, E. NFκB inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc. Natl Acad. Sci. USA 97, 6055-6060 (2000).
113. Farrell, C. J. et al. Inhibition of Epstein-Barr virus-induced growth proliferation by a nuclear antigen EBNA2-TAT peptide. Proc. Natl Acad. Sci. USA 101, 4625-4630 (2004).
114. Kirchmaier, A. L. & Sugden, B. Dominant-negative inhibitors of EBNA-1 of Epstein-Barr virus. J. Virol. 71, 1766-1775 (1997).
115. Rooney, C. M. et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 345, 9-13 (1995). First study to use adoptive transfer of EBV-specific T cells for the treatment of lymphoproliferative disease.
116. Khanna, R. et al. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with post-transplant lymphoproliferative disease. Proc. Natl Acad. Sci. USA 96, 10391-10396 (1999).
117. Haque, T. et al. Treatment of Epstein-Barr virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells. Lancet 360, 436-442 (2002).
118. Roskrow, M. A. et al. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood 91, 2925-2934 (1998).
119. Wagner, H. J. et al. Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15. Cytotherapy 5, 231-240 (2003).
120. + Th1 cells kill Burkitt's lymphoma cells. J. Immunol. 169, 1593-1603 (2002).
121. +/- T cell responses by a chimeric antigen construct: Potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma. J. Virol. 78, 768-778 (2004).
122. Frisan, T. et al. Local suppression of Epstein-Barr virus (EBV)-specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86, 1493-1501 (1995).
123. Wagner, H. J. et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumour environment using tumour antigen-specific T cells. Cancer Gene Ther. 11, 81-91 (2004).
124. Baer, R. et al. DNA sequence and expression of the B95-8 Epstein-Barr virus genome. Nature 310, 207-211 (1984). Sequencing of the prototype strain of EBV - at the time, this was the largest region of DNA ever sequenced and the first human virus to be fully sequenced.
125. Brauninger, A. et al. Epstein-Barr virus (EBV)-positive lymphoproliferations in post-transplant patients show immunoglobulin V gene mutation patterns suggesting interference of EBV with normal B cell differentiation processes. Eur. J. Immunol. 33, 1593-1602 (2003).
126. Brauninger, A. et al. Survival and clonal expansion of mutating 'forbidden' (immunoglobulin receptor-deficient) Epstein-Barr virus-infected B cells in angioimmunoblastic T cell lymphoma. J. Exp. Med. 194, 927-940 (2001).
127. Pathmanathan, R., Prasad, U., Sadler, R., Flynn, K. & Raab-Traub, N. Clonal proliferations of cells infected with Epstein-Barr virus in preinvasive lesions related to nasopharyngeal carcinoma. N. Engl. J. Med. 333, 693-698 (1995). First demonstration of clonal EBV infection in premalignant lesions of the nasopharynx.
128. Lo, K.-W. & Huang, D. P. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin. Cancer Biol. 12, 451-462 (2002). Important review summarizing the genetic and epigenetic events that contribute to the pathogenesis of NPC and indicating that some of these occur before EBV infection.
129. Knox, P. G., Li, Q. X., Rickinson, A. B. & Young, L. S. In vitro production of stable Epstein-Barr virus-positive epithelial cell clones which resemble the virus: cell interaction observed in nasopharyngeal carcinoma. Virology 215, 40-50 (1996).
130. Zhou, S., Fujimuro, M., Hsieh, J. J., Chen, L. & Hayward, S. D. A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J. Virol. 74, 1939-1947 (2000).
131. Artavanis-Tsakonas, S., Matsuno, K. & Fortini, M. E. Notch signaling. Science 268, 225-232 (1995).
132. Sakai, T. et al. Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2. J. Virol. 72, 6034-6039 (1998).
133. Huen, D. S., Henderson, S. A., Groom-Carter, D. & Rowe, M. The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene 10, 549-560 (1995).
134. Eliopoulos, A. G. et al. Epstein-Barr virus-encoded latent infection membrane protein 1 regulates the processing of p100 NFκB2 to p52 via an IKKγ/NEMO-independent signalling pathway. Oncogene 22, 7557-7569 (2003).
135. Dykstra, M. L., Longnecker, R. & Pierce, S. K. Epstein-Barr virus coopts lipid rafts to block the signalling and antigen transport functions of the BCR. Immunity 14, 57-67 (2001).
136. Ikeda, M., Ikeda, A., Longan, L. C. & Longnecker, R. The Epstein-Barr virus latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein ligases. Virology 268, 178-191 (2000).
137. Chen, S.-Y., Lu, J., Shih, Y.-C. & Tsai, C.-H. Epstein-Barr virus latent membrane protein 2A regulates c-Jun protein through extracellular signal-regulated kinase. J. Virol. 76, 9556-9561 (2002).
138. Young, L. S. & Murray, P. G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22, 5108-5121 (2003).